Skip to content
aiqbench takeAI Safety

aiqbench analysis

This paper introduces RES-MR, a Large Language Model framework designed to enhance medication recommendations through explainable clinical reasoning and personalized risk management. By dynamically calibrating safety boundaries based on individual patient profiles rather than fixed constraints, the approach addresses critical gaps in transparency and trust for vulnerable populations. The method successfully balances therapeutic efficacy with tailored safety measures, offering a practical path toward safer AI-driven healthcare decisions.
Source coveringarXiv
What this isA model's reading of the article and related coverage, written for aiqbench. Not the publisher's words.

RES-MR: Risk-Aware Reasoning for Explainable and Safe Medication Recommendation

arXiv2 min read

arXiv:2610.14474v1 Announce Type: cross Abstract: Medication recommendations seek to deliver personalized drug combinations based on patients' clinical information, where ensuring transparent decision-making and personalized safety are of paramount importance. However, existing approaches predominantly operate as ``black boxes'', offering limited interpretability and hindering clinician trust. Furthermore, they typically rely on fixed, patient-agnostic safety constraints, neglecting the heterogeneity of risk tolerance across individuals, which poses significant risks to vulnerable populations. To address these gaps, we propose \textbf{RES-MR}, a novel Risk-aware Reasoning framework for Explainable and Safe Medication Recommendation using LLMs. RES-MR follows a two-stage training paradigm: (1) an explainable clinical reasoning distillation stage to elicit diagnostic capabilities by fine-tuning on synthesized reasoning trajectories, grounded in patient-specific knowledge from graph retrieval; and (2) a risk-aware policy optimization stage to dynamically balance therapeutic efficacy with personalized safety. This stage employs disentangled drug factors to construct patient-specific reference prototypes that capture desired therapeutic drug features and risk features to avoid. These prototypes enable risk boundary calibration and guide the model toward safe recommendations via reward shaping and clipping. Extensive experiments on benchmark datasets demonstrate that RES-MR significantly outperforms state-of-the-art baselines in terms of accuracy, safety, and explainability. Our code and data are available at: https://github.com/wangcong2001/RES-MR.

Abstract:Medication recommendations seek to deliver personalized drug combinations based on patients' clinical information, where ensuring transparent decision-making and personalized safety are of paramount importance. However, existing approaches predominantly operate as ``black boxes'', offering limited interpretability and hindering clinician trust. Furthermore, they typically rely on fixed, patient-agnostic safety constraints, neglecting the heterogeneity of risk tolerance across individuals, which poses significant risks to vulnerable populations. To address these gaps, we propose \textbf{RES-MR}, a novel Risk-aware Reasoning framework for Explainable and Safe Medication Recommendation using LLMs. RES-MR follows a two-stage training paradigm: (1) an explainable clinical reasoning distillation stage to elicit diagnostic capabilities by fine-tuning on synthesized reasoning trajectories, grounded in patient-specific knowledge from graph retrieval; and (2) a risk-aware policy optimization stage to dynamically balance therapeutic efficacy with personalized safety. This stage employs disentangled drug factors to construct patient-specific reference prototypes that capture desired therapeutic drug features and risk features to avoid. These prototypes enable risk boundary calibration and guide the model toward safe recommendations via reward shaping and clipping. Extensive experiments on benchmark datasets demonstrate that RES-MR significantly outperforms state-of-the-art baselines in terms of accuracy, safety, and explainability. Our code and data are available at: this https URL.

Machine Learning (cs.LG); Artificial Intelligence (cs.AI); Information Retrieval (cs.IR)

arXiv:2610.14474 [cs.LG]

(or arXiv:2610.14474v1 [cs.LG] for this version)

https://doi.org/10.48550/arXiv.2610.14474 Focus to learn more arXiv-issued DOI via DataCite (pending registration)

arXivLabs is a framework that allows collaborators to develop and share new arXiv features directly on our website.

Both individuals and organizations that work with arXivLabs have embraced and accepted our values of openness, community, excellence, and user data privacy. arXiv is committed to these values and only works with partners that adhere to them.

Have an idea for a project that will add value for arXiv's community? Learn more about arXivLabs.

Full text under the publisher's open licence · 297 words

Related coverage